The Heifets Laboratory
Welcome to the Heifets Lab
Our research group is dedicated to understanding and improving on powerful, rapid-acting therapies for psychiatric disease, such as ketamine, MDMA and psilocybin. We bridge basic science and clinical trials, connecting neuroscience, psychiatry and anesthesiology in pursuit of highly effective, safe treatment strategies scalable to the millions of patients who need them.
Follow Us on Twitter
;
Thank you Nina Bai @StanfordMed for this beautiful writeup detailing the story of our patient who, after an experience under anesthesia, found peace after the loss of her son. Nice perspectives from the team as well @drpuppychow @PilleriinSikka
Could anesthesia-induced dreams wipe away trauma?
Cases of patients who recovered from trauma after dreaming under surgical anesthesia spur Stanford Medicine researchers ...
scopeblog.stanford.edu
Dr. Harriet de Wit, Professor of Psychiatry and Behavioral Neuroscience at the University of Chicago, will discuss the complexities of trial designs for studies of psychedelic drugs and treatments at Horizons New York on May 10. Learn more, and register at https://buff.ly/3Egr4DU
The placebo effect is strong! 💪
How does non-trip (unconscious) ketamine treatment compare to the placebo? Is this true for all psychedelics?
#ASN2024 #neuroscience #education #placebo #placeboeffect #ketamine #addiction #substanceabuse
I have signed this. Participants and other researchers should have input. Allegations of research misconduct need to be investigated. I also have concerns about the nature of the 'Assisted Therapy' piece, and the potential for MDMA's approval to be tied to this therapy protocol.
Planning to take a psychedelic soon? Please join our study to understand the role of memories in psychedelic experiences at https://tinyurl.com/psmemory!
Anyone planning to take any long-acting psychedelic in any context can join. The first part will take max 10 mins. Please share!
This is important. MDMA has enormous potential… but any potent therapy by definition carries risk. Allegations of trial misconduct are serious and the FDA should, at the least, allow a public hearing. We can’t manage risks we don’t understand.
@EikoFried @IoanaA_Cristea & @NaudetFlorian actually got a paper's title changed (not quite enough, but changed) with a letter to the editor. Worth a read. Even as I do this work I share their concerns about our endeavors to study psychedelic drugs.
Looking forward to presenting on the psychedelic medicine paradigm this Friday at the Center for Neuroscience & Behavior at American University, along with several great colleagues. Looks like virtual attendance is an option.
I wrote about how some people have a higher intolerance of uncertainty, and how being uncomfortable with the unknown is connected to anxiety